After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug

Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). After apparent disappointing results, the companies have chosen to pause the studies with the drug and shift their resources to a similar drug, DNL788, for the same indications. Denali shares dropped almost 7% to $23.95 in late market trading after announcing the decision.